These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31954159)

  • 21. Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.
    Chen MJ; Lin PL; Wang L; Cheng YM; Chen CY; Lee H
    Thorac Cancer; 2020 Jul; 11(7):1904-1910. PubMed ID: 32394538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
    Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
    J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress.
    Chen X; Cao X; Xiao W; Li B; Xue Q
    Aging (Albany NY); 2020 Jan; 12(1):122-137. PubMed ID: 31899687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
    Hayes JD; McMahon M
    Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nrf2 mediates redox adaptation in NOX4-overexpressed non-small cell lung cancer cells.
    Wu Q; Yao B; Li N; Ma L; Deng Y; Yang Y; Zeng C; Yang Z; Liu B
    Exp Cell Res; 2017 Mar; 352(2):245-254. PubMed ID: 28196727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological insights in non-small cell lung cancer.
    Rosell R; Jain A; Codony-Servat J; Jantus-Lewintre E; Morrison B; Ginesta JB; González-Cao M
    Cancer Biol Med; 2023 Jun; 20(7):500-18. PubMed ID: 37381723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
    Qin JJ; Cheng XD; Zhang J; Zhang WD
    Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nrf2 promotes progression of non-small cell lung cancer through activating autophagy.
    Wang J; Liu Z; Hu T; Han L; Yu S; Yao Y; Ruan Z; Tian T; Huang T; Wang M; Jing L; Nan K; Liang X
    Cell Cycle; 2017 Jun; 16(11):1053-1062. PubMed ID: 28402166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance.
    Jeddi F; Soozangar N; Sadeghi MR; Somi MH; Samadi N
    DNA Repair (Amst); 2017 Jun; 54():13-21. PubMed ID: 28415030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
    Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
    Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.
    Liang M; Wang L; Sun Z; Chen X; Wang H; Qin L; Zhao W; Geng B
    Cell Commun Signal; 2022 May; 20(1):62. PubMed ID: 35534896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the Keap1-Nrf2 pathway in cancer.
    Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
    Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression.
    DeBlasi JM; Falzone A; Caldwell S; Prieto-Farigua N; Prigge JR; Schmidt EE; Chio IIC; Karreth FA; DeNicola GM
    Cancer Res; 2023 Jun; 83(12):1953-1967. PubMed ID: 37062029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
    Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
    Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
    Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
    Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.
    Weiss-Sadan T; Ge M; Hayashi M; Gohar M; Yao CH; de Groot A; Harry S; Carlin A; Fischer H; Shi L; Wei TY; Adelmann CH; Wolf K; Vornbäumen T; Dürr BR; Takahashi M; Richter M; Zhang J; Yang TY; Vijay V; Fisher DE; Hata AN; Haigis MC; Mostoslavsky R; Bardeesy N; Papagiannakopoulos T; Bar-Peled L
    Cell Metab; 2023 Mar; 35(3):487-503.e7. PubMed ID: 36841242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPIA dictates NRF2 stability to promote lung cancer progression.
    Lu W; Cui J; Wang W; Hu Q; Xue Y; Liu X; Gong T; Lu Y; Ma H; Yang X; Feng B; Wang Q; Zhang N; Xu Y; Liu M; Nussinov R; Cheng F; Ji H; Huang J
    Nat Commun; 2024 Jun; 15(1):4703. PubMed ID: 38830868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
    Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
    Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.